Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 11/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205153 | 0.83 | L3MBTL1 (0.51) | KMT2AACHEL3MBTL1 | |
| SCHEMBL18030107 | 0.82 | EPHX1 (0.47) | EPHX1MEN1HSP90AA1KMT2AACHE | |
| SCHEMBL11783703 | 0.80 | EPHX1 (0.45) | EPHX1MEN1HSP90AA1KMT2AACHE | |
| SCHEMBL10958696 | 0.80 | EPHX1 (0.45) | EPHX1MEN1HSP90AA1KMT2AACHE | |
| SCHEMBL18531340 | 0.80 | EPHX1 (0.45) | EPHX1MEN1HSP90AA1KMT2AACHE | |
| SCHEMBL8274545 | 0.79 | IDO1 (0.55) | EPHX1MEN1KMT2AIDO1 | |
| SCHEMBL27703730 | 0.79 | MTNR1A (0.50) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL25665600 | 0.78 | EPHX1 (0.44) | EPHX1MEN1HSP90AA1KMT2AACHE | |
| SCHEMBL22449500 | 0.78 | EPHX1 (0.44) | EPHX1MEN1HSP90AA1KMT2AACHE | |
| SCHEMBL18353059 | 0.78 | ATM (0.47) | EPHX1MEN1HSP90AA1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416298-A1 | PRODRUGS OF NEUROACTIVE STEROIDS | BRII BIOSCIENCES, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2020260558-A1 | 3-MODIFIED ISO-/ISOALLO-LITHOCHOLIC ACID DERIVATIVES OR THEIR HOMO-ANALOGS FOR PREVENTING AND TREATING CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416298-A1 | PRODRUGS OF NEUROACTIVE STEROIDS | NR3C1, PGR, GABRD | EPHX1 1488/4885MEN1 3292/4885HSP90AA1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.